Glaucoma: Progression, Life Expectancy & Preserving Vision

What Is Glaucoma?

Glaucoma is a group of optic neuropathies characterized by progressive retinal ganglion cell death and corresponding visual field loss, usually associated with elevated intraocular pressure (IOP). It is a leading cause of irreversible blindness worldwide.

Major Types & Progression Patterns

Type	Mechanism	Progression	Typical Onset
Primary Open-Angle Glaucoma (POAG)	Impaired trabecular outflow	Slow, insidious; peripheral vision loss first	>40 years
Primary Angle-Closure Glaucoma (PACG)	Iris blocks drainage angle	Can be acute (emergency) or chronic	>40, hyperopes, Asians
Normal-Tension Glaucoma (NTG)	IOP statistically “normal” but damaging	Slow; often central visual field loss early	>50, vascular dysregulation
Secondary Glaucomas	Trauma, steroids, inflammation, neovascularization	Variable	Any age
Congenital/Childhood	Developmental angle anomalies	Rapid if untreated	Infancy/childhood

Impact on Lifespan & Quality of Life

Glaucoma does not directly shorten life expectancy. However, it significantly affects quality of life through:

• Progressive visual field constriction → mobility issues, fall risk, driving cessation
• Central vision loss (late) → reading, face recognition impairment
• Medication burden (side effects, cost, adherence)
• Surgical risks (infection, hypotony, cataract)
• Psychological impact: anxiety, depression, loss of independence

Factors Influencing Progression

• IOP control: Lower target IOP slows progression (every 1 mmHg reduction ≈ 10–19% risk reduction)
• Adherence: Consistent drop use is critical; fixed-combination drops improve compliance
• Baseline severity: Advanced damage at diagnosis progresses faster
• Vascular factors: Low perfusion pressure, nocturnal hypotension, sleep apnea
• Genetics: MYOC, OPTN, TBK1, WDR36 variants modify risk
• Lifestyle: Smoking, sedentary behavior may worsen; exercise may lower IOP transiently

Management to Preserve Vision

1. Early detection: Comprehensive exam (IOP, gonioscopy, optic nerve, OCT RNFL, visual field) every 1–2 years >40; earlier if risk factors.
2. Stepwise therapy: Prostaglandin analogs (first-line) → add beta-blocker, alpha-agonist, CAI, rho-kinase inhibitor → laser (SLT) → surgery (trabeculectomy, MIGS, tube shunt).
3. Regular monitoring: IOP q3–6mo; OCT & VF q6–12mo; adjust target IOP based on progression.
4. Neuroprotection (investigational): Nicotinamide, citicoline, brimonidine (possible).

Prognosis With Modern Care

Most patients maintain functional vision lifelong with adherence and monitoring. Blindness is rare in treated populations (<5% at 20 years in POAG). The key is lifelong partnership with an ophthalmologist.